# Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

> **NCT01472939** · PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 480 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** SSP-002358 (0.1 mg) + PPI
- **DRUG:** SSP-002358 (0.5 mg) + PPI
- **DRUG:** SSP-002358 (2.0 mg) + PPI
- **DRUG:** Placebo + PPI

## Key facts

- **NCT ID:** NCT01472939
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-27
- **Primary completion:** 2013-05-14
- **Final completion:** 2013-05-14
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01472939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01472939, "Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT01472939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*